Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P11441

UPID:
UBL4A_HUMAN

ALTERNATIVE NAMES:
Ubiquitin-like protein GDX

ALTERNATIVE UPACC:
P11441; Q5HY80

BACKGROUND:
The BAG6/BAT3 complex, featuring Ubiquitin-like protein 4A, is integral to cellular protein management. It assists in the solubilization of misfolded proteins, their delivery to the endoplasmic reticulum, or their degradation via the proteasome. This complex's role extends to the post-translational delivery of tail-anchored proteins, ensuring cellular homeostasis by preventing the buildup of improperly folded proteins.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Ubiquitin-like protein 4A offers a promising avenue for developing novel therapeutic approaches. Its critical role in maintaining protein homeostasis and preventing protein aggregation makes it a potential target in treating diseases related to protein misfolding.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.